Analytical thin layer chromatography (TLC) was performed with EM Science silica gel 60 F254 aluminium plates. Visualisation was carried out using a UV lamp (254 nm) and by immersion in potassium permanganate (KMnO4), followed by heating using a heat gun. Organic solutions were concentrated by rotary evaporation at 40-45 °C. Purification of reaction products were generally done by flash column chromatography using Fluka Silica, pore size 60Å, 220-440 mesh, 35-75 μm.
S -3 S1. Compound Synthesis and Characterization.
S1.1. Tether Design
Co-crystal structure PDB2a49 was used as a representative b-lactamase in the design of the initial tether length, compound 2. 1 Figure S1 shows the active site of this exemplar b-lactamase (SHV-1) with a b-lactamase inhibitor (linearised, decarboxylated clavulanic acid) covalently bound to Ser70. It was noted that the active site is readily accessible; it was hypothesised that the tether of compound 2 would extend beyond the protein when bound, thus allowing for successful hydrolysis of the surface bound drugs by b-lactamases. Ser70 -compound 2 -surface 1 H and 13 C NMR spectra were recorded on a Jeol ECS 400 (400 MHz for 1 H, 101 MHz for 13 C) at ambient temperature. Chemical shifts are reported relative to residual solvent peaks and coupling constants (J) are given in Hertz. High-resolution ESI mass spectra were recorded on a Bruker microTOF electrospray mass spectrometer. Infrared (IR) spectra were recorded on a PerkinElmer Spectrum Two (ATIR). Analytical HPLC measurements were performed on a Shimadzu HPLC system (Prominence) equipped with a LC-20AD pump, SIL-20A autosampler, DGU-20AS degasser, CTO-20AC column oven, CBM-20A communication bus module and SPD-M20A diode array detector using a SunFire C18 column (Waters, 4.6 x 150 mm, 5 µm). Compound S4, 1,14-diamino-3,6,9,12-tetraoxatetradecane. 2,2'-(3,6,9,12-Tetraoxatetradecane-1,14-diyl)bis(isoindoline-1,3-dione) (S3) (7.6 g, 15.3 mmol, 1 equiv.) was stirred in boiling EtOH (300 mL, 0.05 M) until dissolved. Hydrazine hydrate (23 mL, 0.46 mol, 30 equiv.) was added and the reaction mixture was refluxed for 16 h. The reaction was then allowed to return to room temperature and the resultant precipitate was removed by filtration, washing the filter cake with EtOH. The filtrate was concentrated under reduced pressure and the resultant yellow oil dissolved in DCM (50 mL). A cream precipitate formed, which was then removed by filtration and the filtrate was again concentrated under reduced pressure to afford 1,14-diamino-3,6,9,12-tetraoxatetradecane (S4) quantitatively as a yellow oil, which was used without further purification. 
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Compound S5, tert-butyl N-(14-amino-3,6,9,12-tetraoxatetradecan-1yl)carbamate hydrochloride.
To a solution of 1,14-diamino-3,6,9,12-tetraoxatetradecane (S4) ( To a solution of compound S7 (207 mg, 0.265 mmol, 1 equiv.) in DCM (2 mL, 0.1 M) was added TFA (1 mL) and the resulting solution was stirred at room temperature for 2 h until the deprotection was complete by TLC. The reaction mixture was then concentrated under reduced pressure and azeotroped with DCM (10 mL x 2) to afford the amine, which was used without further purification. The residue was dissolved in MeCN (4 mL, 0.1 M) and then DIPEA (138 µL, 0.795 mmol, 3 equiv.) was added. The pH was confirmed to be pH 10 using pH paper. 6-Maleimidohexanoic acid Nhydroxylsuccinimide ester (S9) (82 mg, 0.265 mmol, 1 equiv.) was then added and the reaction stirred at room temperature. After 16 h the reaction appeared complete by TLC and the solvent was removed under reduced pressure. The residue was then dissolved in EtOAc (15 mL) and washed with 0.1 M HCl (10 mL x 2) and brine (10 mL).
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The organic layer was then collected and concentrated to yellow oil, which was then triturated using Et2O to afford (6R, 7R)-7-((R)-30-(2,5-dioxo-2,5-dihydro-1H-pyrrol- 
Preparation of cephalexin-C6-maleimide (S10), (6R, 7R)-7-((R)-2-(6-(2,5-dioxo-2,5-dihyrdo-1H-pyrrol-1-yl)hexanamido)-2-phenylacetamido)-3-methyl-8-oxo-5thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid:
Compound S10, (6R, 7R)-7-((R)-2-(6-(2,5-dioxo-2,
5-dihyrdo-1H-pyrrol-1yl)hexanamido)-2-phenylacetamido)-3-methyl-8-oxo-5-thia-1azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid.
A solution of cephalexin monohydrate (1.02 g, 2.8 mmol, 1 equiv.) and 6maleimidohexanoic acid N-hydroxylsuccinimide ester (S9) (908 mg, 2.9 mmol, 1.05 equiv.) in anhydrous MeCN (40 mL, 0.6 M) was cooled to 0 °C. DIPEA (1.22 mL, 7 mmol, 2.5 equiv.) was added slowly and the reaction was stirred at 0 °C for 10 min. The reaction mixture was then stirred at room temperature, monitoring the reaction progress by TLC. After 3 h, the solvent was removed under reduced pressure, the residue was then dissolved in EtOAc (20 mL), washed with 0.1 M HCl (20 mL) and then brine (20 mL). The aqueous layer was extracted again with a second portion of EtOAc (20 mL). The combined organics were dried (MgSO4) and concentrated under reduced pressure. The residue was then triturated using Et2O until free-flowing. The cream colour solid was then further triturated using DCM to afford (6R, 7R)-7-((R)-2- S3, 2,2'-(3,6,9,12-tetraoxatetradecane-1,14-diyl) 
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Compound S5, tert-butyl N-(14-amino-3,6,9,12-tetraoxatetradecan-1 
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Compound S6, 2,2-dimethyl-4,21-dioxo-3,8,11,14,17,23,- 
S1.7. Control Thiol Addition
To a solution of compound S10 (50 mg, 0.093 mmol, 1 equiv.) in 3:1, D2O:DMSO-d6 (1 mL) was added cysteine (11 mg, 0.093 mmol, 1 equiv.). The resulting solution was stirred at RT for 3 h after which the reaction was concentrated under reduced pressure. The residue was diluted to 600 uL in DMSO-d6 and analysed by 1 H NMR. Analysis confirmed the b-lactam was still intact, whereas the peak assigned to the maleimide alkene (7.00 ppm) was significantly reduced; thus indicating that the thiol addition occurred preferentially at the maleimide.
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S1.8. Stability of Cephalexin in Urine
Control experiments were carried out using the urine sample to confirm the absence of b-lactamases and the stability of cephalexin in this biological media.
Cephalexin monohydrate (25 mg, 0.68 mmol) was dissolved in 1.5 mL deionised water to produce a 46 mM stock solution. 100 uL of the cephalexin stock solution was then added to 900 uL urine to give a final concentration of 4.6 mM. The resultant solution was then incubated at 37 °C for 24 h. Aliquots were taken for analysis by HPLC after 24 h. Concentration of remaining cephalexin was calculated using the predetermined calibration graph and reported as %remaining, Table S1 . The urine tests were carried out in duplicate with a buffer sample as a control. 
S2. PBP Thermal Shift Assay
To test the binding activity of the purified E. coli PBP3, a thermal shift assay was carried out using the Protein Thermal Shift™ assay kit (Applied Biosystems). 3 µM of purified E. coli PBP3 was mixed with a selection of four b-lactam antibiotics (cephalexin, carbenicillin, amoxicillin, and ampicillin) at 300 µM in a mixture containing the Protein Thermal Shift™ Dye. The samples were then heated in a StepOnePlus™ Real-Time PCR System from 25 to 95 °C at a rate of 1 °C/min. Tests were carried out in triplicate and the averages plotted as the negative first derivative vs. temperature, Figure S2 . Reference wells, i.e. solutions consisting only of only PBP3 with dye, PBP3 only and dye only, were used as controls. Melting temperature (Tm) values were determined with and without carbenicillin, and the change in melting temperature (DTm) was obtained, Table S2 . b-lactamase exposed surface of gold, no functionalisation. Experimental conditions: Once cleaned, sample was immersed in a solution of b-lactamase in 50 mM KPi for 2 h at 37 °C, then gently cleaned with ultrapure water and dried with N2.
Spectrum: IR02 Surface Functionalisation: Cephalexin-PEG-maleimide (2) Description:
Spectra of surface bound cephalexin-PEG. Experimental conditions: Surface post functionalisation, no further reaction. 
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Spectrum:
IR05 Surface Functionalisation: Cephalexin-PEG-maleimide (2) Description:
Spectra of surface bound cephalexin-PEG after exposure to urine. Experimental conditions: Once functionalised, sample was immersed in a urine solution for 24 h at 37 °C, then gently cleaned with 2% SDS, followed by ultrapure water and then dried with N2.
Spectrum: IR06 Surface Functionalisation: Cephalexin-PEG-maleimide (2) Description:
Spectra of surface bound cephalexin-PEG before urine spiked with b-lactamase. Experimental conditions: Sample functionalised, analysed prior to urine test. Spectra of surface bound cephalexin-PEG after exposure to urine spiked with b-lactamase. Experimental conditions: Once functionalised, sample was immersed in a urine solution spiked with b-lactamase for 24 h at 37 °C, then gently cleaned with 2% SDS, followed by ultrapure water and then dried with N2.
Spectrum: IR08 Surface Functionalisation: Cephalexin-PEG-maleimide (2) Description:
Spectra of surface bound cephalexin-PEG after washing with solution of SDS. Experimental conditions: Once functionalised, sample was gently cleaned with 2% SDS, followed by ultrapure water and then dried with N2. 
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Spectrum: IR11 Surface Functionalisation: Cephalexin-C6-maleimide (S10) Description:
Spectra of surface functionalised with cephalexin-C6. Experimental conditions: Surface post functionalisation, no further reaction.
Spectrum:
IR12 Surface Functionalisation: Cephalexin-C6-maleimide (S10) Description:
Spectra of surface functionalised with cephalexin-C6 post enzyme hydrolysis. Experimental conditions: Once functionalised, sample was immersed in a solution of b-lactamase in 50 mM KPi for 2 h at 37 °C, then gently cleaned with ultrapure water and dried with N2. 
S3.2. QCM-D Analysis -Sauerbrey Equation
Surface concentrations from QCM-D data were calculated using the Sauerbrey equation. We note, this model assumes a thin, rigid, and uniform layer, and is therefore only an estimated value. Spectra comparing the binding of cephalexin-PEG to both Au and SiO2.
Experimental conditions:
Running order: 1-KPi; 2-cephalexin-PEG (2); 3-KPi.
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Data:
QCM02 Surface Functionalisation:
Cephalexin-C6 (S10) on Au and SiO2 sensors; Cephalexin-PEG (2) on Au and SiO2 sensors Description:
Spectra comparing b-lactamase fouling of cephalexin-C6 and cephalexin-PEG surfaces on both Au and SiO2.
Experimental conditions:
Running order: 1-KPi; 2-b-lactamases; 3-KPi; 4-2% SDS; 5-KPi.
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QCM03 Surface Functionalisation:
Cephalexin-PEG (2) on Au sensors. Sensor (3) exposed to 1 M NaOH for 30 min Description:
Spectra comparing the binding of PBP to cephalexin-PEG (2) on Au.
Experimental conditions:
Running order: 1-KPi; 2-PBP(1&3)/PBP-ceph conjugate (2); 3-KPi; 4-2% SDS; 5-KPi
Data:
QCM04 Surface Functionalisation:
Cephalexin-PEG (2) on SiO2 sensors. Sensor (3) exposed to 1 M NaOH for 30 min Description:
Spectra comparing the binding of PBP to cephalexin-PEG (2) on SiO2.
Experimental conditions:
